USA Rare Earth
USAR
$10.40
+16.72%
USA Rare Earth, Inc. is a vertically integrated developer of a domestic U.S. rare earth element and critical minerals supply chain, focused on building an NdFeB magnet manufacturing plant alongside upstream extraction and processing capabilities intended to serve the energy, mobility, and national security end markets. The company is best characterized as a pre-revenue, policy-backed strategic asset rather than an operating industrial — a nascent challenger to China's dominance in rare earth processing and magnet production, with only 132 employees and a single reportable segment. The investor narrative has swung violently between two poles: a government-backed bull case built on a $1.2 billion South Carolina magnet facility, a reported $3.5 billion funding base, and a pending Serra Verde acquisition with revenue guarantees that could flip the company from cash-burning to cash-generative, versus a bear case centered on massive shareholder dilution, negative gross margins, a legal dispute with MP Materials, and China's export restrictions on U.S. rare earth firms. Most recently the bear case has dominated price action, with the stock down roughly 61% over the past year despite repeated analyst Buy reiterations, leaving the market to debate whether the strategic scarcity value of a domestic mine-to-magnet chain can survive the company's cash burn and equity overhang.…
USAR
USA Rare Earth
$10.40
Related headlines
Investment Opinion: Should I buy USAR Today?
Rating: Hold (speculative, catalyst-dependent). The core thesis is that USAR is a policy-backed strategic option on a domestic mine-to-magnet supply chain, not an operating industrial — and at $9.33, just 0.8% above its 52-week low, the market is pricing in substantial execution and dilution risk that the sell-side's $35.56 average target has not yet marked to reality. The 9-analyst consensus is uniformly bullish (Needham, Roth, Wedbush, Cantor, Canaccord all Buy/Outperform), but the 114% spread between the $21 low and $45 high target signals low conviction, and the 281% implied upside is a red flag for stale estimates rather than a near-term call.
Supporting evidence for holding rather than selling: the balance sheet is fortress-like with debt-to-equity of 0.0062 and a current ratio of 10.17, cash stands at $1.594 billion, and the $3.5 billion funding base plus government purchase guarantees give the company runway to execute. Revenue has stabilized sequentially at $5.7-$5.8 million in Q1-Q2 2026 versus zero in the prior three quarters, and the Q2 net loss narrowed to -$10.3 million from Q1's -$67.0 million. However, the negatives are equally concrete: gross margin of -69.82%, TTM FCF of -$245.5 million, PS of 709.95x versus a low-to-mid single-digit sector norm, and a share count that has more than doubled year-over-year. The forward PE of 311.0x and consensus revenue estimate of ~$3.04 billion imply a >200x ramp that is years away.
The biggest risks that could invalidate the thesis are Serra Verde failing to close, further dilution, and a breakdown below the $9.26 support level. This Hold would upgrade to Buy if Serra Verde closes with revenue guarantees intact and the stock bases above $14-$15, or downgrade to Sell if the stock decisively breaks $9.26 or another equity raise is announced. On valuation, the stock is overvalued on every current fundamental metric but fairly-to-attractively valued as a strategic option relative to its own de-rating trajectory (PS compressed from 1,072x at Q4 2025 to 709.95x now, PB from 3.58x to 2.37x). This is an objective, data-driven assessment, not personalized financial advice.
Sign up to view all
USAR 12-Month Price Forecast
The forward view is genuinely balanced: the balance sheet ($1.594 billion cash, negligible debt, 10.17 current ratio) and government-backed funding give USAR time, but the operating reality (-69.82% gross margin, -$245.5 million TTM FCF, 709.95x PS) means the equity is a binary bet on Serra Verde and plant commissioning rather than a fundamentals story. The technical picture — at the 52-week low with accelerating downside momentum and -74.34% relative strength versus SPY — argues against catching the falling knife before a base forms. I would upgrade to bullish if the stock bases above $14-$15 and Serra Verde closes with guarantees intact, and downgrade to bearish if $9.26 breaks decisively or another raise is announced. With a 2.684 beta and 3.51-day short ratio, position sizing must be dramatically smaller than a market-beta allocation. The 50% base-case probability reflects that the most likely path is range-bound stabilization in the low-to-mid teens, not a return to the $35 analyst target.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on USA Rare Earth's 12-month outlook, with a consensus price target around $35.13 and implied upside of +237.7% versus the current price.
Average Target
$35.13
0 analysts
Implied Upside
+237.7%
vs. current price
Analyst Count
—
covering this stock
Price Range
$21 - $45
Analyst target range
Coverage is robust for a company of this size, with 9 analysts and a consensus average target price of $35.56 — implying roughly +281% upside from the current $9.33, an extraordinarily wide gap that reflects stale targets rather than near-term conviction. The recommendation field is listed as "none," but the institutional ratings history shows a uniformly bullish tape: Needham (Buy), Roth Capital (Buy), Wedbush (Outperform), Cantor Fitzgerald (Overweight), and Canaccord Genuity (Buy) have all reiterated positive ratings through 2026, with no downgrades recorded. The consensus therefore leans strongly bullish, but the divergence between a $35.56 target and a $9.33 price is a red flag — either the market is mispricing the stock by a factor of nearly four, or the analyst targets have not yet been marked to the post-dilution, post-selloff reality.\n\nThe target range of $21.00 to $45.00 is exceptionally wide (a 114% spread from low to high), signaling high uncertainty and low conviction in any single price objective. The high target of $45.00 implicitly assumes successful plant commissioning, the Serra Verde acquisition closing with government revenue guarantees, and multiple expansion on a transformed revenue base; the low target of $21.00 — still 125% above the current price — prices in continued execution but with margin compression and dilution. Notably, the estimated EPS average of $2.145 (range $1.47–$3.02) implies the Street expects a dramatic swing to profitability, which is inconsistent with the current -$0.0526 quarterly EPS and suggests estimates are forward-looking to a post-ramp period. Given that the stock trades 77% below the lowest analyst target, the practical read is that targets are aspirational and the market is discounting significant execution, financing, and dilution risk that the sell-side has not yet incorporated.
Drowning in data?
Find the real signal!
Bulls vs Bears: USAR Investment Factors
The bear case currently holds the stronger evidence: the stock is down 61.21% over one year and 41.06% in the last month alone, trading 0.8% above its 52-week low with negative gross margins (-69.82%), a TTM free cash flow burn of -$245.5 million, and a 709.95x PS multiple that prices in a >200x revenue ramp. The bull case rests almost entirely on forward-looking, binary events — the Serra Verde acquisition closing with revenue guarantees and the $1.2 billion South Carolina plant commissioning — rather than any demonstrated operating leverage. The single most important tension is whether the government-backed funding and purchase contracts can convert cash burn into cash generation before the next dilution cycle; if Serra Verde closes on terms, the thesis flips, but if it slips or dilutes further, the equity overhang compounds. Analyst targets of $35.56 average are stale relative to the post-dilution reality and should be discounted heavily, leaving the market's verdict — a stock at the bottom of its range — as the more credible signal today.
Bullish
- Government-backed funding base of $3.5B: USA Rare Earth has assembled a reported $3.5 billion funding base, including $1.5 billion of common stock issued in Q1 2026 that lifted cash to $1.594 billion at end of Q2 2026. This capital, combined with Pentagon-linked critical minerals funding programs, gives the company an unusually deep war chest for a 132-employee pre-revenue developer.
- Serra Verde deal could flip cash flow: The pending Serra Verde acquisition carries government-backed revenue guarantees that, if closed, could transform USAR from a cash-burning developer into a cash-generative mine-to-magnet producer. This is the single largest swing factor in the thesis and the basis for the Street's forward revenue estimate of ~$3.04 billion.
- Strategic scarcity as sole domestic chain: USAR is building a vertically integrated NdFeB magnet plant in South Carolina ($1.2 billion facility) with upstream extraction and processing, positioning it as a direct challenger to China's dominance in rare earth processing. China's export restrictions on U.S. rare earth firms paradoxically validate this strategic value and accelerate Western supply-chain independence.
- Balance sheet solvency is not the issue: Debt-to-equity of 0.0062 and a current ratio of 10.17 mean near-term solvency risk is minimal despite a TTM free cash flow of -$245.5 million. The company has runway to execute on plant commissioning without an immediate distressed financing.
Bearish
- Negative gross margin on every sale: Q2 2026 revenue of $5.821 million came against cost of revenue of $9.885 million, producing gross profit of -$4.064 million and a gross margin of -69.82%. The business loses money on each dollar of sales, and TTM net margin of -181.11% with operating margin of -36.22% shows opex ($42.25 million in Q2) dwarfing the revenue base.
- Massive dilution and equity overhang: Shares outstanding ballooned from 148.055 million in Q4 2025 to 196.479 million in Q2 2026 after $1.5 billion of stock issuance, and the count was just 92.8 million in Q2 2025. This dilution is the direct cause of much of the 61.21% one-year decline and remains an overhang for any future capital raise.
- Valuation is a pure option premium: Trailing PS of 709.95x and EV/Sales of 58.17x sit more than 100x above the low-to-mid single-digit sector norm, while forward PE of 311.0x and a consensus revenue estimate of ~$3.04 billion imply a >200x revenue ramp. There is no margin of safety on current fundamentals — the price is a policy thesis, not a valuation thesis.
- Falling-knife technicals at 52-week low: At $9.33 the stock sits just 0.8% above its 52-week low of $9.26, with a max drawdown of -75.88% and a 1-month decline of -41.06% that is steeper than the 3-month -34.06%. Relative strength of -74.34% versus SPY over one year confirms idiosyncratic distribution, not sector beta.
USAR Technical Analysis
USAR is in a sustained, unrelenting downtrend, with the 1-year price change of -61.21% and a 6-month decline of -57.32% reflecting a collapse from a 52-week high of $32.80 to the current $9.33. At $9.33, the stock sits just 0.8% above its 52-week low of $9.26 — effectively at the very bottom of its 52-week range (roughly 0.3% of the range from the low) — a positioning that signals capitulation and falling-knife dynamics rather than a value opportunity, particularly given a max drawdown of -75.88% from peak. With the stock making fresh lows into late October, there is no evidence of base-building or accumulation; the trend remains firmly negative until proven otherwise.\n\nShort-term momentum is accelerating to the downside and diverging sharply from an already weak longer-term trend: the 1-month change of -41.06% is worse than the 3-month change of -34.06%, meaning the pace of decline has steepened in the most recent month rather than stabilized. Relative strength confirms broad-based underperformance — -40.04% versus SPY over 1 month and -74.34% over 1 year, against a flat-to-positive SPY (+13.13% 1-year) — indicating this is idiosyncratic selling pressure, not sector beta. Volume of roughly 9.6 million shares on the latest session suggests heavy distribution, and the short ratio of 3.51 days-to-cover implies meaningful short interest that could amplify either further downside or a violent squeeze on any positive catalyst.\n\nKey technical levels are stark: support is the 52-week low at $9.26, and a decisive breakdown below that level would open air with no historical reference points, likely triggering momentum-driven selling and stop-loss cascades. Resistance sits at the 52-week high of $32.80, with intermediate supply likely in the $14–$20 zone where the stock repeatedly failed during its August–September rallies. The beta of 2.684 is the critical risk-management input — the stock is roughly 168% more volatile than the market, meaning a 1% SPY move implies a ~2.7% USAR move, so position sizing must be dramatically smaller than a market-beta allocation and stop-losses must be wide enough to avoid noise-driven exits.
Beta
2.68
2.68x market volatility
Max Drawdown
-77.0%
Largest decline past year
52-Week Range
$9-$33
Price range past year
Annual Return
-51.9%
Cumulative gain past year
| Period | USAR Return | S&P 500 |
|---|---|---|
| 1m | -31.5% | -0.2% |
| 3m | -20.4% | +5.5% |
| 6m | -60.0% | +7.1% |
| 1y | -51.9% | +12.3% |
| ytd | -26.5% | +12.9% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
USAR Fundamental Analysis
Revenue is nascent and erratic rather than on a clean growth trajectory: Q2 2026 revenue of $5.821 million followed Q1 2026 revenue of $5.698 million and Q4 2025 revenue of $1.643 million, with the prior three quarters (Q1–Q3 2025) reporting zero revenue. The sequential stabilization around $5.7–$5.8 million is a modest positive, but the cost of revenue of $9.885 million in Q2 exceeded revenue, producing negative gross profit of -$4.064 million — meaning the business currently loses money on every dollar of sales. With no revenue segment disclosure available, the investment case rests entirely on future magnet plant capacity rather than any demonstrated operating leverage, and the analyst consensus revenue estimate of ~$3.04 billion (range $2.31B–$4.00B) implies a step-function transformation that is years, not quarters, away.\n\nProfitability is deeply negative and structurally challenged: Q2 2026 net income was -$10.333 million (EPS -$0.0526), Q1 2026 was -$66.989 million (EPS -$0.34), and Q4 2025 was -$50.205 million (EPS -$0.37), with the Q1 loss inflated by a -$31.97 million other-income swing. Gross margin of -69.82% in Q2 improved from -35.06% in Q1 on a ratio basis but remains deeply negative, while the TTM net margin of -181.11% and operating margin of -36.22% underscore that operating expenses ($42.25 million in Q2, including $10.768 million of R&D and $31.482 million of SG&A) dwarf the revenue base. The one genuine positive is that the Q2 net loss of -$10.3 million narrowed dramatically from Q1's -$67.0 million, aided by $33.838 million of net other income and $370,000 of interest income — but this is balance-sheet-driven, not operational, and the underlying EBITDA of -$43.833 million in Q2 shows the core business is burning cash at scale.\n\nThe balance sheet is the company's lifeline and its biggest risk: cash at end of Q2 2026 stood at $1.594 billion (up from $1.750 billion at the start of the quarter), funded by $1.500 billion of common stock issued in Q1 2026 — a massive dilution event that explains much of the share count expansion to 196.479 million from 148.055 million in Q4 2025. Debt is negligible (debt-to-equity of 0.0062, current ratio of 10.17), so solvency risk is low near-term, but free cash flow TTM of -$245.521 million and Q2 FCF of -$126.615 million (including $69.747 million of capex) mean the company is consuming capital at a rate that will require further raises absent a transformative deal. ROE of -60.40% and ROA of -4.45% confirm capital destruction, and the FCF yield is negative by definition — the investment hinges entirely on whether the Serra Verde acquisition and government-backed purchase contracts can convert this cash burn into cash generation before the next dilution cycle.
Quarterly Revenue
$5821000.0B
2026-06
Revenue YoY Growth
N/A
YoY Comparison
Gross Margin
-69.8%
Latest Quarter
Free Cash Flow
$-245521000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Open an Account, get $2 TSLA now!
Valuation Analysis: Is USAR Overvalued?
Because net income is negative (TTM EPS of -$0.2551, trailing PE of -3.60), the PE ratio is not meaningful, and I therefore lead with the price-to-sales ratio as the primary metric: the trailing PS of 709.95x is extreme, while the forward PE of 311.0x and EV/Sales of 58.17x reflect a market that is pricing in the analyst consensus revenue estimate of ~$3.04 billion against current TTM revenue of roughly $13 million. The enormous gap between trailing and forward multiples implies the market expects a revenue ramp of more than 200x — a bet on plant commissioning and the Serra Verde deal rather than on any current earnings power.\n\nPeer comparison is difficult because USAR has no direct domestic comparable at scale, but against the broader Basic Materials/Industrial Materials sector — where PS multiples typically range in the low-to-mid single digits — USAR's 709.95x PS and 58.17x EV/Sales represent a premium of well over 100x the sector norm. Even against rare earth peer MP Materials, which has actual production and revenue, USAR's valuation is a pure option premium on future capacity. The premium is not justified by current profitability (gross margin -69.82%, net margin -181.11%) or returns (ROE -60.40%); it is justified only by strategic scarcity — a domestic mine-to-magnet chain backed by government funding and purchase guarantees — which is a policy thesis, not a valuation thesis.\n\nHistorical context is limited given the March 2025 listing, but the trajectory is telling: the PS ratio has compressed from 1,072.34x at Q4 2025 to 728.40x at Q2 2026 and 709.95x currently, while the PB ratio has fallen from 3.58x to 2.37x — the stock is de-rating toward, but remains far above, any historical norm. The PEG ratio of -0.0049 is meaningless given negative earnings, and the negative PCF of -23.81 reflects cash burn. In short, the market is still pricing in highly optimistic long-term expectations even after a 61% decline; the valuation offers no margin of safety on current fundamentals and is entirely dependent on execution of the South Carolina facility and the Serra Verde transaction.
PE
-3.6x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 2x~28x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
-14.0x
Enterprise Value Multiple
Investment Risk Disclosure
Financial and operational risks are acute and quantifiable. Q2 2026 gross profit was -$4.064 million on $5.821 million of revenue (gross margin -69.82%), meaning the company loses money on every sale, while operating expenses of $42.25 million (including $10.768 million R&D and $31.482 million SG&A) dwarf the revenue base. TTM free cash flow of -$245.5 million, including $69.747 million of Q2 capex, means the company consumes capital at a rate that will require further raises absent a transformative deal, and the share count already expanded from 148.055 million to 196.479 million in a single quarter. ROE of -60.40% and ROA of -4.45% confirm ongoing capital destruction, and the Q2 net loss narrowing to -$10.3 million was driven by $33.838 million of net other income, not operations — underlying EBITDA was -$43.833 million.
Market and competitive risks center on valuation compression and external threats. At 709.95x trailing PS and 58.17x EV/Sales versus a low-to-mid single-digit sector norm, the stock carries enormous multiple-compression risk if the revenue ramp disappoints, and the forward PE of 311.0x leaves no cushion. The beta of 2.684 means a 1% SPY move implies roughly a 2.7% USAR move, so any macro risk-off rotation would hit this name disproportionately — already visible in the -74.34% one-year relative strength versus a +13.13% SPY. Competitive and regulatory headwinds include China's export restrictions on U.S. rare earth firms, a legal dispute with MP Materials, and execution risk on the $1.2 billion South Carolina facility, all of which can trigger sharp drawdowns in a stock with a 3.51-day short ratio that amplifies moves in both directions.
The worst-case scenario is a specific chain: Serra Verde fails to close or closes on dilutive terms, the South Carolina plant commissioning slips, and the company returns to equity markets for another raise into a stock already at its lows. That would break support at the 52-week low of $9.26, opening air with no historical reference points and likely triggering momentum-driven selling and stop-loss cascades. From the current $9.33, a break to the 52-week low is only about -0.8%, but the realistic downside extends well beyond — the max drawdown of -75.88% from the $32.80 peak illustrates how far this name can fall, and a further 30-50% decline toward the mid-single digits is plausible if the binary catalysts fail. Investors should size positions for a potential -50% or worse outcome, not the -0.8% to the stated low.
FAQ
Ranked by severity: first, financial risk — gross margin of -69.82% and TTM free cash flow of -$245.5 million mean the company burns capital at scale and will likely need further raises, with the share count already up from 148.055 million to 196.479 million in one quarter. Second, company-specific binary risk — the Serra Verde acquisition and the $1.2 billion South Carolina plant are the entire thesis, and a delay or dilutive renegotiation would be devastating. Third, valuation and market risk — a 709.95x PS multiple and 2.684 beta mean any multiple compression or macro risk-off rotation hits this name roughly 2.7x the market, already visible in -74.34% one-year relative strength. Fourth, competitive and geopolitical risk — China's export restrictions on U.S. rare earth firms and the legal dispute with MP Materials add unresolved overhangs. The balance sheet (debt-to-equity 0.0062, current ratio 10.17) mitigates near-term solvency risk but not equity dilution risk.
The three-scenario framework assigns a 50% base case of $12-$18, a 30% bear case of $5-$9.26, and a 20% bull case of $21-$45. The base case is most likely: incremental progress on the plant and Serra Verde but a revenue ramp still years away, keeping the stock range-bound in the low-to-mid teens and capped by the $14-$20 supply zone where it repeatedly failed in August-September. The key base-case assumption is that Serra Verde closes without a new equity raise, given the $1.594 billion cash balance. The bear case aligns with the 52-week low of $9.26 and below, triggered by deal slippage or dilution, while the bull case requires both execution and a favorable policy backdrop to reach the $21-$45 analyst range. The 50% base-case weighting reflects that stabilization, not a return to the $35.56 average target, is the most probable outcome.
On every current fundamental metric, USAR is dramatically overvalued: trailing PS of 709.95x, EV/Sales of 58.17x, and forward PE of 311.0x sit more than 100x above the low-to-mid single-digit sector norm for Basic Materials. The market is paying a pure option premium on a >200x revenue ramp implied by the ~$3.04 billion consensus estimate versus roughly $13 million of TTM revenue. That said, the stock has de-rated meaningfully — PS compressed from 1,072.34x at Q4 2025 to 709.95x now, and PB fell from 3.58x to 2.37x — so it is less overvalued than it was at the peak. The valuation implies the market expects successful plant commissioning and the Serra Verde deal, but the 61.21% one-year decline shows investors are increasingly discounting execution and dilution risk. It is overvalued on fundamentals and fairly-to-attractively valued only as a strategic option relative to its own history.
From a risk/reward perspective, USAR is a high-risk, catalyst-dependent bet rather than a clean buy. The stock at $9.33 sits just 0.8% above its 52-week low of $9.26, with a -41.06% one-month decline and -74.34% one-year relative underperformance versus SPY, so the technical trend is firmly negative. The reward side is real — 9 analysts average a $35.56 target, and even the $21 low target implies 125% upside — but those targets look stale relative to the post-dilution reality of 196.479 million shares. The biggest downside risk is a break below $9.26 combined with another equity raise, which could drive the stock toward the mid-single digits. It is a good buy only for risk-tolerant investors who can size it as a small optional allocation and who believe Serra Verde closes with guarantees intact; for most investors, waiting for a base above $14-$15 is the more prudent path.
USAR is suitable primarily for long-term, risk-tolerant investors with a minimum three-to-five-year holding period, because the value proposition — a domestic mine-to-magnet supply chain — will not be realized until the South Carolina plant commissions and Serra Verde integrates, which is years away. The beta of 2.684 and max drawdown of -75.88% make it unsuitable for short-term traders unless they are explicitly trading the binary catalysts with tight risk controls, and the 3.51-day short ratio means squeezes and cascades can be violent in both directions. There is no dividend (yield 0%, payout ratio 0), so there is no income component to support a holding. Earnings visibility is essentially nil given negative gross margins and erratic revenue, so position sizing should be a small fraction of a normal allocation. A concrete suggested minimum holding period is three years, with a willingness to add only after a technical base forms above $14-$15.